AUTOMATED SCREENING WITH CONFIRMATION OF MECHANISM-BASED INACTIVATION OF CYP3A4, CYP2C9, CYP2C19, CYP2D6, AND CYP1A2 IN POOLED HUMAN LIVER MICROSOMES

A strategy is proposed to profile compounds for mechanism-based inactivation of CYP3A4, CYP2C19, CYP2C9, CYP2D6, and CYP1A2 based on an apparent partition ratio screen. Potent positives from the screen are confirmed by time- and concentration-dependent inactivation assays. Quasi-irreversible inhibitions are then differentiated from irreversible inactivations by oxidation with potassium ferricyanide and/or dialysis. The three-step screening procedure has been validated with acceptable accuracy and precision for detection and confirmation of mechanism-based inactivators in drug discovery. We report here the apparent partition ratios for 19 mechanism-based inactivators and four quasi-irreversible inhibitors obtained under the same experimental conditions. The apparent partition ratio screen was automated to provide throughput for determining structure-mechanism-based inactivation relationships. Information about reversibility can be used to assess potential toxicity mediated by covalent adducts, as well as the potential for pharmacokinetic drug-drug interactions. Direct comparison of known mechanism-based inactivators and quasi-irreversible inhibitors, based on our screening of apparent partition ratios, has identified ritonavir, mibefradil, and azamulin as highly effective mechanism-based inactivators; e.g., 1 mol of CYP3A4 was inactivated on turnover of about 2 mol of compound. Other mechanism-based inactivators we identified include bergamottin (CYP1A2 besides previously reported CYP3A4), troglitazone (CYP3A4), rosiglitazone (CYP3A4), and pioglitazone (CYP3A4). Comparison of the apparent partition ratios and inactivation clearance data for the three glitazones suggests that the chromane moiety on troglitazone contributes to its greater potency for mechanism-based inactivation.

[1]  J. Uetrecht,et al.  N-OXIDATION OF DRUGS ASSOCIATED WITH IDIOSYNCRATIC DRUG REACTIONS , 2002, Drug metabolism reviews.

[2]  T. Baillie,et al.  Studies on the metabolism of troglitazone to reactive intermediates in vitro and in vivo. Evidence for novel biotransformation pathways involving quinone methide formation and thiazolidinedione ring scission. , 2001, Chemical research in toxicology.

[3]  S. O. Kim,et al.  Characterization of the selectivity and mechanism of cytochrome P450 inhibition by dimethyl-4,4'-dimethoxy-5,6,5',6'-dimethylenedioxybiphenyl-2,2'-dicarboxylate. , 2001, Drug metabolism and disposition: the biological fate of chemicals.

[4]  L. Benet,et al.  Antiprogestin-Mediated Inactivation of Cytochrome P450 3A4 , 1998, Pharmacology.

[5]  P. Hollenberg,et al.  Mechanism-based inactivation of cytochrome P450 3A4 by 17 alpha-ethynylestradiol: evidence for heme destruction and covalent binding to protein. , 2002, The Journal of pharmacology and experimental therapeutics.

[6]  Amy Roe,et al.  The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[7]  D. Sica,et al.  Rhabdomyolysis and statin therapy: relevance to the elderly. , 2002, The American journal of geriatric cardiology.

[8]  Shiew-Mei Huang,et al.  Optimizing drug development: Strategies to assess drug metabolism/transporter interaction potential‐toward a consensus , 2001 .

[9]  Honglu Zhang,et al.  A method for the simultaneous evaluation of the activities of seven major human drug-metabolizing cytochrome P450s using an in vitro cocktail of probe substrates and fast gradient liquid chromatography tandem mass spectrometry. , 2001, Drug metabolism and disposition: the biological fate of chemicals.

[10]  K. He,et al.  Mechanism-based inactivation of cytochrome P-450-3A4 by mifepristone (RU486). , 1999, The Journal of pharmacology and experimental therapeutics.

[11]  K. Koeplinger,et al.  Microsomal metabolism of delavirdine: evidence for mechanism-based inactivation of human cytochrome P450 3A. , 1998, The Journal of pharmacology and experimental therapeutics.

[12]  J. Watson,et al.  Introduction to mass spectrometry , 1985 .

[13]  Y. Horsmans,et al.  Pharmacokinetic-Pharmacodynamic Relationships of H1-Antihistamines , 1995, Clinical pharmacokinetics.

[14]  P. Hollenberg,et al.  Mechanism-Based Inactivation of Cytochrome P-450-3 A 4 by Mifepristone ( RU 486 ) 1 , 1999 .

[15]  E. Burton,et al.  Prediction of in vivo drug interactions with eplerenone in man from in vitro metabolic inhibition data , 2004, Xenobiotica; the fate of foreign compounds in biological systems.

[16]  M. Delaforge,et al.  Particular ability of cytochromes P450 3A to form inhibitory P450-iron-metabolite complexes upon metabolic oxidation of aminodrugs. , 1995, Biochemical pharmacology.

[17]  R. Kitz,et al.  Esters of methanesulfonic acid as irreversible inhibitors of acetylcholinesterase. , 1962, The Journal of biological chemistry.

[18]  S. D. Turner,et al.  Highly selective inhibition of human CYP3Aa in vitro by azamulin and evidence that inhibition is irreversible. , 2004, Drug metabolism and disposition: the biological fate of chemicals.

[19]  Shiew-Mei Huang.  Drug-Drug Interactions , 2004 .

[20]  W. Trager,et al.  Isoform-selective mechanism-based inhibition of human cytochrome P450 1A2 by furafylline. , 1993, Chemical research in toxicology.

[21]  M. Murray,et al.  Mechanisms of inhibitory and regulatory effects of methylenedioxyphenyl compounds on cytochrome P450-dependent drug oxidation. , 2000, Current drug metabolism.

[22]  J. Goldstein,et al.  Ticlopidine as a selective mechanism-based inhibitor of human cytochrome P450 2C19. , 2001, Biochemistry.

[23]  R. Obach,et al.  Validated assays for human cytochrome P450 activities. , 2004, Drug metabolism and disposition: the biological fate of chemicals.

[24]  P. Neuvonen,et al.  Isoniazid is a mechanism-based inhibitor of cytochrome P450 1A2, 2A6, 2C19 and 3A4 isoforms in human liver microsomes , 2001, European Journal of Clinical Pharmacology.

[25]  A. Kalgutkar,et al.  Mechanism-based inactivation of human recombinant P450 2C9 by the nonsteroidal anti-inflammatory drug suprofen. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[26]  D. Greenblatt,et al.  Apparent mechanism-based inhibition of human CYP2D6 in vitro by paroxetine: comparison with fluoxetine and quinidine. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[27]  H. Yamazaki,et al.  Inhibitory effects of amiodarone and its N-deethylated metabolite on human cytochrome P450 activities: prediction of in vivo drug interactions. , 2000, British journal of clinical pharmacology.

[28]  S. Clarke,et al.  Characterization of the inhibition of P4501A2 by furafylline. , 1994, Xenobiotica; the fate of foreign compounds in biological systems.

[29]  B. Ma,et al.  Metabolic interactions between mibefradil and HMG-CoA reductase inhibitors: an in vitro investigation with human liver preparations. , 1999, British journal of clinical pharmacology.

[30]  M. Franklin.  Cytochrome P450 metabolic intermediate complexes from macrolide antibiotics and related compounds. , 1991, Methods in enzymology.

[31]  B McNutt,et al.  Torsades de pointes occurring in association with terfenadine use. , 1991, JAMA.

[32]  A. D. Rodrigues,et al.  Drug-drug interactions , 2001, Atkinson's Principles of Clinical Pharmacology.

[33]  Daniel L. Purich,et al.  Contemporary enzyme kinetics and mechanism , 1996 .

[34]  D. Mansuy,et al.  Thiophene derivatives as new mechanism-based inhibitors of cytochromes P-450: inactivation of yeast-expressed human liver cytochrome P-450 2C9 by tienilic acid. , 1994, Biochemistry.

[35]  B. W. Penman,et al.  Microtiter plate assays for inhibition of human, drug-metabolizing cytochromes P450. , 1997, Analytical biochemistry.

[36]  A. Nomeir,et al.  Improved reliability of the rapid microtiter plate assay using recombinant enzyme in predicting CYP2D6 inhibition in human liver microsomes. , 1999, Drug Metabolism And Disposition.

[37]  P. Dayer,et al.  Drug–drug interactions of new active substances: mibefradil example , 1999, European Journal of Clinical Pharmacology.

[38]  G. Dive,et al.  Coumarinic derivatives as mechanism-based inhibitors of alpha-chymotrypsin and human leukocyte elastase. , 2000, Bioorganic & medicinal chemistry.

[39]  D. Wysowski,et al.  Cisapride and fatal arrhythmia. , 1996, The New England journal of medicine.

[40]  B. Ma,et al.  Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[41]  Y. Masubuchi,et al.  Diclofenac-induced inactivation of CYP3A4 and its stimulation by quinidine. , 2002, Drug metabolism and disposition: the biological fate of chemicals.